At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- ALN-4285 (drug), Placebo (drug)
- How long the study runs
- Study runs about 15 months (dates as stated)
- About the drug or intervention
- ALN-4285 — drug: ALN-4285 will be administered SC · Placebo — drug: Placebo will be administered SC
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years to 65 Years
- Who
- All
- Number of participants
- 76
- Started
- 2025-12-12
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for healthy volunteers
- • Phase1 - 76 participants
- • The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers * characterize the single-dose pharmacokinetics (PK) of ALN-4285
Who can take part?
- • Ages 18 Years to 65 Years
- • Diagnosed with healthy volunteers
Where?
- • London - Clinical Trial Site
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers * characterize the single-dose pharmacokinetics (PK) of ALN-4285
Healthy Volunteers
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 65 Years
- Who can join: All genders
Biomarkers mentioned
eGFR
What the study is looking for
- ✓Has a body mass index (BMI) of ≥18.0 kg/m\^2 and ≤30 kg/m\^2
- ✓Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator
Who cannot take part
- ✗Has alanine aminotransferase (liver enzymes) or aspartate aminotransferase (liver enzymes) \>upper limit of normal (ULN)
- ✗Has total liver blood test \>ULN
- ✗Has systolic blood pressure \>140 mmHg and/or a diastolic blood pressure \>90 mmHg
- ✗Has an estimated glomerular filtration (eGFR) of \<90 mL/min/1.73m\^2 at screening
- ✗Has received an investigational agent within the last 30 days or 5 half-lives
See the full criteria
Inclusion Criteria:
* Has a body mass index (BMI) of ≥18.0 kg/m\^2 and ≤30 kg/m\^2
* Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator
Exclusion Criteria:
* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN)
* Has total bilirubin \>ULN
* Has systolic blood pressure \>140 mmHg and/or a diastolic blood pressure \>90 mmHg
* Has an estimated glomerular filtration (eGFR) of \<90 mL/min/1.73m\^2 at screening
* Has received an investigational agent within the last 30 days or 5 half-lives
Where Is This Study? (1 UK site)
Clinical Trial Site
London NW10 7EW, United Kingdom
How to Get in Touch
Clinical Trial Information Line
Sponsor contactCONTACT
1-877-ALNYLAM clinicaltrials@alnylam.com
Clinical Trial Information Line
Sponsor contactCONTACT
1-877-256-9526 clinicaltrials@alnylam.com
Data sourced from ClinicalTrials.gov · Last verified: 2026-09